Mereo BioPharma (MREO) Assets Average (2018 - 2026)

Mereo BioPharma (MREO) has reported Assets Average for 6 consecutive years, with $37.7 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Assets Average fell 42.48% year-over-year to $37.7 million in Q2 2026; TTM through Jun 2026 was $37.7 million, a 42.48% decrease from a year earlier, with the FY2025 full-year figure at $61.2 million, down 14.4% from the prior year.
• Assets Average was $37.7 million for Q2 2026 at Mereo BioPharma, down from $43.3 million in the prior quarter.
• Over five years, Assets Average peaked at $92.4 million in Q3 2024 and troughed at $37.7 million in Q2 2026.
• A 3-year average of $63.9 million and a median of $63.3 million in 2024 frame the typical range for Assets Average.
• Across the five-year window, Assets Average gained 18.19% in 2025 and slumped 42.48% in 2026, its largest moves.
• Over 3 years, Assets Average stood at $82.6 million in 2024, then slumped by 39.74% to $49.8 million in 2025, then slipped by 24.31% to $37.7 million in 2026.
• The last three Assets Average figures came in at $37.7 million (Q2 2026), $43.3 million (Q1 2026), and $49.8 million (Q4 2025), per Business Quant data.